REQUIREMENTS FOR SAFETY AND QUALITY OF INTRAVENOUS IMMUNOGLOBULIN-G PREPARATIONS

被引:14
|
作者
RUTTER, GH
机构
[1] Serapharm Division of Research and Development, Seraphann GmbH, D-48155 Munster
来源
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 1994年 / 57卷
关键词
D O I
10.1136/jnnp.57.Suppl.2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The increasing use of intravenous immunoglobulin-G preparations (IVIg) calls for evaluation of the requirements for quality and freedom from infection. The WHO Requirements dating from 1982 have been surpassed by the majority of IVIg preparations. Three methods are used for ensuring safety from infection: the restrictive choice of donor, the precise introductory screening of every individual blood or plasma donation, and the additional active virus inactivation procedures that surpass the virus elimination of, for example, the Cohn-fractionation method. Although it is highly improbable that IVIg can transfer infections, this possibility cannot be completely ruled out even when all the GMP (good manufacturing practice) rules are observed most carefully. Increased safety from infection would be provided if blood and plasma donations were obtained nationally from unpaid voluntary donors and if an additional active viral inactivation procedure was introduced.
引用
收藏
页码:2 / 5
页数:4
相关论文
共 50 条
  • [1] EVALUATING THE QUALITY OF IMMUNOGLOBULIN-G PREPARATIONS FOR INTRAVENOUS THERAPY
    NYDEGGER, UE
    VOX SANGUINIS, 1985, 49 : 1 - 7
  • [2] IMMUNOGLOBULIN-G SUBCLASS DISTRIBUTION IN 3 HUMAN INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS
    BURCKHARDT, JJ
    GARDI, A
    OXELIUS, VA
    PREUDHOMME, JL
    SCHERZ, R
    SKVARIL, F
    HEINIGER, HJ
    VOX SANGUINIS, 1989, 57 (01) : 10 - 14
  • [3] THE SAFETY OF INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS
    WEISMAN, LE
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1994, 30 (5-6): : 459 - 463
  • [4] IMMUNOMODULATORY EFFECTS OF INTRAVENOUS IMMUNOGLOBULIN-G
    SCHIFFERLI, JA
    DIDIERJEAN, L
    SAURAT, JH
    JOURNAL OF RHEUMATOLOGY, 1991, 18 (06) : 937 - 939
  • [5] CROHN DISEASE AND INTRAVENOUS IMMUNOGLOBULIN-G
    KNOFLACH, P
    MULLER, C
    EIBL, MM
    ANNALS OF INTERNAL MEDICINE, 1990, 112 (05) : 385 - 386
  • [6] 3 GENERATIONS OF IMMUNOGLOBULIN-G PREPARATIONS FOR CLINICAL USE
    MCCUE, JP
    HEIN, RH
    TENOLD, R
    REVIEWS OF INFECTIOUS DISEASES, 1986, 8 : S374 - S381
  • [7] SAFETY AND TOXICITY OF A NEW SERUM IMMUNOGLOBULIN-G INTRAVENOUS PREPARATION, IGIV PH 4.25
    PIROFSKY, B
    REVIEWS OF INFECTIOUS DISEASES, 1986, 8 : S457 - S463
  • [8] INTRAVENOUS IMMUNOGLOBULIN-G (IGIV) PREPARATIONS CONTAIN HIGH-TITER ANTIBODIES TO BACTERIAL EXOTOXIN SUPERANTIGENS
    HAREL, W
    MCKELVEY, T
    MAMIDI, R
    UEMURA, Y
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A233 - A233
  • [9] ROLE OF INTRAVENOUS IMMUNOGLOBULIN-G IN AUTOIMMUNE HEMATOLOGIC DISORDERS
    BLANCHETTE, VS
    KIRBY, MA
    TURNER, C
    SEMINARS IN HEMATOLOGY, 1992, 29 (03) : 72 - 82
  • [10] PROTEOLYTIC ACTIVITY IN PREPARATIONS OF PURIFIED IMMUNOGLOBULIN-G AND RABBIT ANTIBODIES
    KULBERG, AY
    DOCHEVA, YV
    TARKHANO.IA
    SPIVAK, VA
    BIOCHEMISTRY-MOSCOW, 1969, 34 (06) : 956 - &